Nemaura Medical

What Nemaura Medical does

Nemaura Medical Inc. is a UK-based medical technology company headquartered in Loughborough and traded publicly under the ticker NMRD. Founded in 2011, the company develops non-invasive wearable glucose monitoring devices, principally the sugarBEAT continuous glucose monitor and the proBEAT sensor, both designed to eliminate the need for finger-prick blood draws that are standard in conventional glucose testing. The company's stated differentiator is the non-invasive form factor, targeting continuous data capture for diabetes management rather than episodic sampling.

The product portfolio is anchored on proprietary wearable sensor hardware paired with digital health programs that the company describes as a recurring subscription offering. Nemaura supplements glucose monitoring devices with content acquired via its 2020 purchase of Healthimation, broadening the offering into wellness and behavior-change content adjacent to diabetes management. The company is engaged in clinical studies with the UK NHS and pursues regulatory pathways in both the UK and US, with parallel commercial efforts directed at Saudi Arabia's high-prevalence diabetes market and its Vision 2030 health initiatives.

Nemaura's business model combines hardware sales of its wearable sensors with subscription-based digital health programs, and it is currently in the commercialization ramp-up phase across three target geographies: the United Kingdom, the United States, and Saudi Arabia. Capital has been raised primarily through non-dilutive debt facilities from a single existing lender, totaling approximately $21.5 million across three rounds in 2022–2023, supplemented by an earlier $25 million of equity-led funding from Chicago Venture Partners in 2020–2021. The company has 11–50 employees and no disclosed revenue figures, indicating pre-commercial to nominal early-sales status.

Name

Nemaura Medical

Legal name

Nemaura Medical Inc.

Website

https://nemauramedical.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Nemaura Medical is a UK-based medical technology company developing non-invasive wearable glucose monitoring devices (sugarBEAT and proBEAT) and digital health programs, targeting diabetes patients and healthcare providers across the UK, US, and Saudi Arabia.

Ownership category

akta.pro rank

Product category

Continuous Glucose Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)

akta.pro secondary industries

Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE), Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate) (HLAHAOAB), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Non-invasive glucose monitoring
• Continuous glucose monitoring devices
• Wearable biosensors
• Diabetes management technology
• Digital health programs

Headquarters

HQ city

Loughborough

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Others

Revenue model

1. Glucose Monitoring Technologies: Revenue from commercializing wearable glucose sensors including sugarBEAT and proBEAT products. Company is in ramp-up phase of commercialization.
2. Digital Health Programs: Revenue from digital health programs and wellness offerings related to glucose monitoring

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Nemaura Medical develops and commercializes non-invasive wearable glucose monitoring devices, with sugarBEAT® and proBEAT™ as its flagship products providing continuous glucose tracking without finger-prick blood sampling. Alongside the hardware, the company delivers digital health programs and wellness offerings to support diabetes management for patients and healthcare providers in the UK, US, and Saudi markets.

Product overview

Nemaura Medical develops and commercializes non-invasive wearable glucose sensors for continuous glucose monitoring. The company's product portfolio includes sugarBEAT® and proBEAT™ as its core glucose monitoring devices. The company also offers digital health programs alongside its hardware products, targeting the diabetes management market with ongoing regulatory efforts in the UK and US.

Differentiator

Problem solved

Functional benefit

Brands

• sugarBEAT: Non-invasive wearable glucose monitor
• proBEAT

Products and services

• sugarBEAT® Non-invasive wearable glucose sensor providing continuous glucose monitoring for individuals managing diabetes, eliminating the need for finger-prick blood sampling.
• proBEAT™ Non-invasive wearable glucose sensor offered as part of Nemaura Medical's glucose monitoring product portfolio for diabetes management and wellness monitoring.
• Nemaura Digital Health Programs Digital health and wellness program offerings paired with Nemaura Medical's glucose monitoring hardware, supporting ongoing glucose tracking, wellness monitoring, and diabetes management for patients.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Know Labs: Know Labs is developing a non-invasive glucose monitoring technology (Bio-RFID). Most comparable emerging competitor pursuing the same non-invasive CGM thesis that Nemaura's sugarBEAT® targets.
• Senseonics Holdings: Senseonics developed the Eversense implantable CGM, an alternative continuous monitoring approach. Comparable as an emerging CGM innovator pursuing non-traditional glucose sensing modalities.
• Insulet Corporation: Insulet's Omnipod tubeless insulin patch pump is part of the integrated CGM-plus-pump diabetes ecosystem, intersecting Nemaura's connected glucose monitoring roadmap and digital health ambitions.

Direct peers

• LifeScan: LifeScan (OneTouch) is a global blood glucose monitoring franchise, historically BGM-focused and now expanding into digital diabetes management — the closest large-scale direct peer in diabetes monitoring devices.
• Ascensia Diabetes Care: Ascensia (Contour blood glucose meters) is a leading diabetes monitoring company that has been transitioning toward connected digital diabetes solutions, comparable to Nemaura's hardware-plus-digital-program model.
• Dexcom: Dexcom is the leading continuous glucose monitoring (CGM) company (G7, G6). It is the most direct competitor to Nemaura's sugarBEAT® in the CGM category, targeting the same diabetes patient and provider population.

Broad incumbents

• Medtronic Diabetes: Medtronic offers Guardian CGM integrated with its insulin pumps, competing broadly across diabetes monitoring and automated insulin delivery — overlapping with Nemaura's glucose sensor and digital health vision.
• Roche Diabetes Care: Roche operates the Accu-Chek franchise spanning BGM, insulin delivery, and digital diabetes management. Comparable as a broad incumbent operating across the same diabetes patient journey Nemaura addresses.
• Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the dominant CGM franchise globally. As a diversified diagnostics giant, Abbott competes head-on with Nemaura's continuous monitoring model across consumer and clinical channels.

Regional players

• Ypsomed: Ypsomed is a Switzerland-headquartered diabetes care company (mylife BGM, insulin pump platforms). Comparable as a European diabetes devices and digital health player, particularly relevant to Nemaura's UK/NHS channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nemaura-medical-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nemaura Medical